RT Journal Article
SR Electronic
T1 A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.01.21259831
DO 10.1101/2021.07.01.21259831
A1 Low, Jenny G.
A1 de Alwis, Ruklanthi
A1 Chen, Shiwei
A1 Kalimuddin, Shirin
A1 Leong, Yan Shan
A1 Mah, Tania Ken Lin
A1 Yuen, Natalene
A1 Tan, Hwee Cheng
A1 Zhang, Summer L
A1 Sim, Jean X.Y.
A1 Chan, Yvonne F.Z.
A1 Syenina, Ayesa
A1 Yee, Jia Xin
A1 Ong, Eugenia Z.
A1 Sekulovich, Rose
A1 Sullivan, Brian B.
A1 Lindert, Kelly
A1 Sullivan, Sean B.
A1 Chivukula, Pad
A1 Hughes, Steven G.
A1 Ooi, Eng Eong.
YR 2021
UL http://medrxiv.org/content/early/2021/07/02/2021.07.01.21259831.abstract
AB Background The pandemic of coronavirus disease-19 (Covid-19) continues to afflict the lives and livelihoods of many as global demand for vaccine supply remains unmet.Methods Phase 1 of this trial (N=42) assessed the safety, tolerability and immunogenicity of ascending levels of one-dose ARCT-021, a self-amplifying mRNA vaccine against Covid-19. Phase 2 (N=64) tested two-doses of ARCT-021 given 28 days apart. Both young and older adults were enrolled. The primary safety outcomes were local and systemic solicited adverse events (AEs) reported immediately and up to 7 days post-inoculation and unsolicited events reported up to 56 days after inoculation. Secondary and exploratory outcomes were antibody and T cell responses to vaccination, respectively.Results ARCT-021 was well tolerated up to one 7.5 μg dose and two 5.0 μg doses. Local solicited AEs, namely injection-site pain and tenderness, as well as systemic solicited AEs, such as fatigue, headache and myalgia, were more common in ARCT-021 than placebo recipients, and in younger than older adults. Seroconversion rate for anti-S IgG was 100% in all cohorts except for the 1 μg one-dose in younger adults and the 7.5 μg one-dose in older adults, which were each 80%. Neutralizing antibody titers increased with increasing dose although the responses following 5.0 μg and 7.5 μg ARCT-021 were similar. Anti-S IgG titers overlapped with those in Covid-19 convalescent plasma. ARCT-021 also elicited T-cell responses against the S glycoprotein.Conclusion Taken collectively, the favorable safety and immunogenicity profiles support further clinical development of ARCT-021.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04480957Funding StatementThis trial was sponsored by Arcturus Therapeutics Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SingHealth Centralized Institutional Review Board (CIRB F/2020/2553) and the Singapore Health Sciences Authority.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request and with necessary approvals from the corresponding author.